Drug intelligence / Profile preview

AAN-xxx

Development stage: Preclinical
Lead developer: Aanastra
Modality: Peptides, Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

AAN-xxx refers to a series of preclinical RNA therapy programs developed by DIVINCELL in collaboration with undisclosed partners. These programs utilize the proprietary PEP-NP™ (peptide-based nanoparticle) delivery platform to transport RNA payloads into target cells. According to company pipeline information, these collaborative efforts include programs aimed at treating genetic diseases through enzyme replacement therapy. The PEP-NP™ technology is designed to provide a stable and efficient delivery mechanism for various RNA modalities, overcoming common challenges associated with nucleic acid delivery.

Beyond the preview

Go deeper on AAN-xxx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAN-xxx.

Explore the full profile